Literature DB >> 8180014

Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.

J Ma1, J Verweij, H J Kolker, H E van Ingen, G Stoter, J H Schellens.   

Abstract

The profiles of an i.v. bolus and 3 h and 20 h infusion of cisplatin (CDDP) were simulated in vitro by using a culture of the IGROV1 human ovarian cancer cell line. Disappearance of pharmacologically active unbound CDDP was accomplished by adding human albumin to the medium. Total and unbound CDDP and CDDP-DNA adduct levels were quantitated by atomic absorption spectroscopy (AAS), and tumour cell survival was measured by the clonogenic assay. The design of the experiment resulted in non-significant differences in the magnitude of the area under the concentration-time curve (AUC) of unbound CDDP between the three dose-input functions (AUC i.v. bolus, 6.34 +/- 0.36; 3 h infusion, 6.35 +/- 0.59; and 20 h infusion, 6.76 +/- 0.40 micrograms h ml-1). Also, the differences between the area under the CDDP-DNA adduct-time curves (AUA) of the three dose-input functions were not significant. The initial rate of decline of the CDDP-DNA adduct-time curve was significantly higher for the i.v. bolus and 3 h infusion than for the 20 h infusion. There was a log-linear relationship between the AUC of unbound CDDP and cell survival. These relationships were not significantly different between the three dose-input functions. Variation in the rate of input of CDDP leads to differences in the shape of the AUC and AUA without significant effects on cell survival.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8180014      PMCID: PMC1968910          DOI: 10.1038/bjc.1994.166

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

Review 1.  Continuous infusion chemotherapy: a critical review.

Authors:  N J Vogelzang
Journal:  J Clin Oncol       Date:  1984-11       Impact factor: 44.544

2.  Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration.

Authors:  V Troger; J L Fischel; P Formento; J Gioanni; G Milano
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

Review 3.  Drugs five years later. Cisplatin.

Authors:  P J Loehrer; L H Einhorn
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

4.  Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity.

Authors:  A C Plooy; M van Dijk; P H Lohman
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

5.  Cis-diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity.

Authors:  P Salem; M Khalyl; K Jabboury; L Hashimi
Journal:  Cancer       Date:  1984-02-15       Impact factor: 6.860

6.  Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice.

Authors:  J Bénard; J Da Silva; M C De Blois; P Boyer; P Duvillard; E Chiric; G Riou
Journal:  Cancer Res       Date:  1985-10       Impact factor: 12.701

7.  Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration.

Authors:  J B Vermorken; T S Kapteijn; A A Hart; H M Pinedo
Journal:  Eur J Cancer Clin Oncol       Date:  1983-01

8.  Influence of combination chemotherapy with cis-diamminedichloroplatinum on renal function: long-term effects.

Authors:  S Meijer; N H Mulder; D T Sleijfer; A J Donker; W J Sluiter; P E de Jong; H Schraffordt Koops; G K van der Hem
Journal:  Oncology       Date:  1983       Impact factor: 2.935

9.  24-hour infusion of cis-platinum in head and neck cancers.

Authors:  C Jacobs; J R Bertino; D R Goffinet; W E Fee; R L Goode
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

10.  Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications.

Authors:  J B Vermorken; W J van der Vijgh; I Klein; H E Gall; H M Pinedo
Journal:  Eur J Cancer Clin Oncol       Date:  1982-11
View more
  6 in total

1.  A mathematical model for cisplatin cellular pharmacodynamics.

Authors:  Ardith W El-Kareh; Timothy W Secomb
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

2.  The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor.

Authors:  C S Straathof; M J van den Bent; J Ma; P I Schmitz; J M Kros; G Stoter; C J Vecht; J H Schellens
Journal:  J Neurooncol       Date:  1998-03       Impact factor: 4.130

3.  Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor.

Authors:  J Ma; Z L Fei; A Klein-Szanto; J M Gallo
Journal:  Clin Exp Metastasis       Date:  1998-08       Impact factor: 5.150

4.  Cisplatin Pharmacodynamics Following Endobronchial Ultrasound-Guided Transbronchial Needle Injection into Lung Tumors.

Authors:  Vitor Mori; Gregory S Roy; Jason H T Bates; C Matthew Kinsey
Journal:  Sci Rep       Date:  2019-05-02       Impact factor: 4.379

5.  Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.

Authors:  J Ma; J Verweij; A S Planting; M de Boer-Dennert; H E van Ingen; M E van der Burg; G Stoter; J H Schellens
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

6.  Efficacy and Safety of Human Serum Albumin-Cisplatin Complex in U87MG Xenograft Mouse Models.

Authors:  Cho Rong Park; Hyo Young Kim; Myung Geun Song; Yun-Sang Lee; Hyewon Youn; June-Key Chung; Gi Jeong Cheon; Keon Wook Kang
Journal:  Int J Mol Sci       Date:  2020-10-26       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.